impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Case Reports

 

CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis

1, 2, 3, 4

 

  1. Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy.
  2. Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy.
  3. Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy.
  4. Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy. gff1990@gmail.com

CER8443
2016 Vol.34, N°2
PI 0315, PF 0317
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 26575162 [PubMed]

Received: 11/03/2015
Accepted : 23/07/2015
In Press: 17/11/2015
Published: 13/04/2016

Abstract

We describe a patient suffering from seropositive rheumatoid arthritis (RA) and type I diabetes mellitus (T1DM), who achieved a good EULAR response together with an improvement of the glycemic profile under treatment with CTLA-4 Ig. A close association is known to exist between T1DM and RA, and CTLA-4 exon 1 polymorphism has been associated to RA with coexisting autoimmune endocrinopathies. The possible common genetic background and the potential role of CTLA-4 Ig in the early phases of T1DM, could be considered in the therapeutic interventions in RA patients with type 1 diabetes.

Rheumatology Article